Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ведение токсичности, обусловленной иммунотерапией: клинические рекомендации ESMO по диагностике, лечению и последующему наблюдению
2017-05-05
SCID: 54.1/xqpq4fue
Discuss with AI
CTLA4PD-1/PD-L1immune checkpoint inhibitorsimmune-related adverse eventsimmunotherapy toxicities
Figures from the paper
Abstract (AI)
Immunotherapy with monoclonal antibodies (MoAbs) targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and the programmed death-1 receptor (PD-1) and its ligand PD-L1 has become standard of care for an increasing number of indications (Table 1). Therefore, an increasing number of patients will be exposed to these drugs with a chance of developing toxicities from these treatments. Depending on the immune checkpoint that is targeted, the incidence of toxicity varies. Toxicities from immune checkpoint inhibitors (ICPis) can be divided into infusion reactions and immune-related adverse events (irAEs) or adverse events of special interest (AEoSI).
Key Findings
1
As immunotherapy use expands, more patients will be exposed to treatment-related toxicities requiring systematic diagnosis, management, and follow-up.
2
Checkpoint inhibitor toxicities comprise infusion reactions and immune-related adverse events, also termed adverse events of special interest.
3
Immune checkpoint inhibitors targeting CTLA4, PD-1, and PD-L1 have become standard care across an increasing number of clinical indications.
4
The incidence of immune checkpoint inhibitor toxicity varies according to the immune checkpoint targeted.
Research Object
Toxicities from immune checkpoint inhibitor immunotherapy, including infusion reactions and immune-related adverse events
Research Subject
Diagnosis, treatment, and follow-up management of toxicities associated with CTLA4-, PD-1-, and PD-L1-targeting monoclonal antibodies
Publication Details
Publication Date
2017-05-05
Journal
Publisher
ISSN
Cited by
2416
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest